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Prevalence and Outcomes of Unoperated Patients With
Severe Symptomatic MR and Heart Failure
(A) Pie chart showing mechanism and management of 1,095 patients with severe
symptomatic MR. (B) Mortality and rates of hospitalization for heart failure in
unoperated patients with severe MR. DMR ¼ degenerative mitral regurgitation;
FMR ¼ functional mitral regurgitation; MR ¼ mitral regurgitation; MV ¼ mitral
valve. Figure by Craig Skaggs.To the Editor: Mitral valve (MV) surgery is recommended in
patients with severe symptomatic mitral regurgitation (MR) (1).
The role of MV surgery is unclear in patients with severe MR
secondary to left ventricular (LV) dysfunction (1). Many patients
with severe MR are at high surgical risk due to advanced age, LV
dysfunction, or comorbidities. The MitraClip device (Abbott
Vascular, Abbott Park, Illinois) provides a novel percutaneous
option for patients with severe MR with signiﬁcant improvement
(2,3). However, the characteristics and outcomes of this patient
population remain unclear. We sought to assess the characteristics
and outcomes of patients with severe symptomatic MR who do not
undergo MV surgery and their potential eligibility for MitraClip.
Our institutional databases showed that 5,737 patients with se-
vere (3þ) MR were identiﬁed between January 1, 2000, and
December 31, 2008. A search of the electronic medical records
yielded 1,095 patients with a diagnosis of severe MR and heart
failure. Patients undergoing MV surgery until September 30,
2011, were identiﬁed. Exclusion criteria included MV area
2 cm2, aortic regurgitation of grade 2/4 or greater, aortic peak
velocity 2.5 m/s, hypertrophic cardiomyopathy, active endo-
carditis, concomitant aortic valve, aortic or pericardial surgeries, left
ventricular assist device implantation, or heart transplantation.
Diagnosis and procedures were conﬁrmed by chart review. Patients
with unoperated functional MR (FMR) were evaluated regarding
eligibility for MitraClip based on published criteria.
FMR (814 of 1,095 [74%]) and degenerative MR (DMR)
(226 of 1,095 [21%]) were the predominant mechanisms of MR.
MV surgery was performed in 47% (518 of 1,095) of patients,
whereas 53% (577 of 1,095) of patients were unoperated and
medically managed (Fig. 1A). The etiology was FMR and DMR in
57% (294 of 518) and 37% (190 of 518) of the operated and 90%
(520 of 577) and 6% (36 of 577) of the unoperated patients,
respectively. In the FMR group, 36% (294 of 814) of patients
underwent MV surgery and 64% (520 of 814) were medically
managed, whereas 84% (190 of 226) of patients with DMR
underwent MV surgery and 16% (36 of 226) were medically
managed. Unoperated patients had a lower ejection fraction
(27  15% vs. 42  17%, p < 0.0001 [Student t test]) and a higher
Society of Thoracic Surgeons score compared with operated
patients (median [interquartile range]: 5.8 [2.8 to 11.5] vs. 4.0
[2.1 to 7.4], p < 0.001 [Student t test]).
The overall 1-year and 5-yearmortality rate in unoperated patients
was 20% and 50%, respectively (Fig. 1B). In these unoperated pa-
tients, the proportion of surviving patients hospitalized for heart
failure increased from 41% in the ﬁrst year to 90% by 5 years. Of 474unoperated patients with symptomatic severe FMR with a good-
quality echocardiogram available for review, 171 patients (36%)
would have been eligible for MitraClip based on published criteria.
Over a mean follow-up period of 4.5 years, an increase in use of
the following medical therapies was observed in unoperated patients
with MR: angiotensin-converting enzyme inhibitors (31% to 63%),
angiotensin receptor blockers (13% to 25%), beta-blockers (35%
to 82%), and aldosterone antagonists (13% to 33%). Cardiac
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186resynchronization therapy was instituted in 17% (100 of 577) and
percutaneous coronary revascularization in 10% (58 of 577) of
unoperated patients. At the end of follow-up, the severity of MR
improved to less than grade 2þ in 15% of patients (89 of 577).
In the Euro Heart Survey (396 patients with severe MR), 56%
and 32% of patients with DMR and FMR, respectively, did not
undergo surgery (4). In contrast, we found that the majority of
patients with DMR underwent surgery and the vast majority (90%)
of unoperated patients had FMR. This likely reﬂects the low risk
and better durability of surgical MV repair for DMR compared
with FMR in a center with surgical expertise and excellence. In
contrast, many patients with FMR do not undergo MV surgery
unless coronary artery bypass grafting is feasible and indicated (77%
in our cohort of patients with ischemic FMR) when concomitant
MV surgery is usually performed.
The current class IIb recommendation for MV surgery in the
presence of LV dysfunction is based on lack of survival beneﬁt and a
high recurrence rate ofMR (5). The outcomes of medically managed
patients, however, remain understudied. Our observations highlight
the poor outcomes of medically managed patients with severe FMR
with a 1-year mortality rate of 20%, 5-year mortality rate of 50%,
and high rate of heart failure hospitalization. Until recently, medi-
cally managed patients with FMR had no good options short of
advanced mechanical support and heart transplantation. MitraClip
provides an important new tool for FMR with good clinical
improvement and safety (30-day mortality rate of 1%) (2). Non-
randomized studies have shown a clinical beneﬁt of MitraClip in
high-risk patients with FMR (3). Our study identiﬁes a potentially
large unmet need for transcatheter MR reduction strategies in
medically managed patients. In this context, the ongoing studies
that are enrolling high surgical risk patients with severe FMR will
provide data on the effectiveness of MitraClip in these patients.
This was a single-center observational study from a large tertiary
referral center. It is possible that some patients with severe MR
were hospitalized outside our network of hospitals, resulting in an
underestimation of hospitalization rates. Not all patients were
necessarily referred to a cardiothoracic surgeon. However, this
mirrors current clinical practice, where the role of surgery for FMR
remains nebulous. Finally, anatomic criteria for MitraClip are
evolving with increasing experience, underestimating the potential
applicability of this therapy.
In conclusion, our analysis not only highlights a substantial
unmet need for MitraClip for symptomatic patients with severe
MR but also provides some benchmark data on their outcomes
with medical management.Sachin S. Goel, MDy
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Computed Tomography for
Diagnosis of Prosthetic
Valve Endocarditis
Increased Valvular 18F-Fluorodeoxyglucose
Uptake as a Novel Major CriterionWe read with great interest the recent publication by Saby et al. (1),
in which 72 patients with suspected prosthetic heart valve (PHV)
endocarditis were prospectively studied to determine the accuracy
